Metsera, Maze Therapeutics

Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs
A pair of drugmakers priced their initial public offerings on Thursday, delivering the best month for US health care first-time share sales since October.
Two more biotechs, Metsera and Maze, cross IPO finish line
Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.
Metsera, Inc IPOs Tomorrow, Here's What You Need To Know
Metsera, Inc MTSR IPO will take place January, 31 on the NASDAQ exchange under the ticker MTSR. The company is offering shares at an expected price between $15.00 and $17.00 per share with an insider lock-up period of 180 days ending on July 30, 2025.
Metsera IPO opens 42% higher
Metsera, a clinical-stage biotechnology firm, debuted on the Nasdaq Global Select Market today. After initially offering its common stock to the public at $18.00 per share, the company's shares opened for trading at a higher price of $25.
Google Ventures-Backed Biotech Metsera Seeks $292 Million in IPO
Metsera Inc. is seeking to raise $292 million in an initial public offering, joining a clutch of health-care firms set to make their debuts as public companies.
Metsera, Maze secure combined $415 million in IPOs
The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go public.
Weight-loss drug developer Metsera raises $275 million in US IPO
Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company said on Thursday.
Metsera Announces Pricing of Initial Public Offering
A registration statement on Form S-1 (File No. 333-284225) relating to the offering has been filed with the Securities and Exchange Commission and became effective on January 30, 2025. The offering is ...
Obesity-drug maker Metsera posts largest gain as IPOs defy market swoon
Oil company Natural Resources and medical-device maker Beta Bionics shrug off a down market to gain in their trading debuts.
FierceBiotech2d
Busy day for biotech IPOs as Metsera, Maze go public with offerings totaling nearly $400M
Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. | Obesity biotech Metsera and ...
Seeking Alpha19d
Obesity drug developer Metsera files for $100M IPO
Metsera (MTSR), which is developing ultra-long-acting drugs for the treatment of obesity, has filed for a $100M initial public offering. While the company didn't specify terms in its SEC ...